Which statement about hyperthyroidism is correct?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Graves' Disease is the Most Common Cause of Hyperthyroidism

Statement A is correct: Graves' disease is indeed the most common cause of hyperthyroidism. According to authoritative guidelines and recent research, Graves' disease accounts for approximately 70% of hyperthyroidism cases and has a global prevalence of 2% in women and 0.5% in men 1, 2, 3, 4.

Analysis of Each Statement

Statement A: Graves' Disease as Most Common Cause ✓ CORRECT

Multiple high-quality sources confirm this:

  • Graves' disease represents 70% of hyperthyroidism cases 4
  • Other common causes include toxic nodular goiter (16%), thyroiditis (3%), and drug-induced hyperthyroidism (9%) 1, 2, 4
  • The U.S. prevalence of hyperthyroidism is approximately 1.2% (0.5% overt, 0.7% subclinical), with Graves' disease being the predominant etiology 2, 3

Statement B: More Common in Men ✗ INCORRECT

Graves' disease is actually more common in women:

  • Female sex is a documented risk factor for hyperthyroidism 1
  • Global prevalence: 2% in women versus 0.5% in men 3
  • This represents a 4:1 female-to-male ratio

Statement C: Majority After Age 60 ✗ INCORRECT

Hyperthyroidism does not predominantly occur after age 60:

  • While advancing age is a risk factor for thyroid dysfunction generally 1, hyperthyroidism affects all age groups
  • The prevalence is approximately 1.2% in the general U.S. population 2
  • Subclinical hyperthyroidism occurs in about 1% of men and 1.5% of women over age 60 5, but this does not represent the majority of cases

Statement D: Not Accompanied by Autoantibodies ✗ INCORRECT

Autoantibodies are frequently present in hyperthyroidism:

  • Graves' disease (the most common cause) is an autoimmune condition characterized by TSH-receptor antibodies 1, 6
  • Hashimoto thyroiditis, which can cause hyperthyroidism, involves thyroid peroxidase antibodies 4
  • The presence of autoantibodies is actually a key diagnostic feature in many hyperthyroidism cases

Statement E: Nodules Necessary for Diagnosis ✗ INCORRECT

Nodules are not required for hyperthyroidism diagnosis:

  • Graves' disease typically presents with a diffusely enlarged thyroid gland without discrete nodules 3
  • Diagnosis is based on biochemical tests (low TSH, elevated free T4 and/or T3) 1, 4
  • While toxic nodular goiter and toxic adenoma involve nodules, these account for only a minority of cases
  • Thyroid ultrasound is not recommended as first-line diagnostic testing 6

Clinical Implications

The correct identification of Graves' disease as the most common cause has important treatment implications. Common causes of hyperthyroidism include Graves' disease, Hashimoto thyroiditis, and functional thyroid nodules, with treatment options including antithyroid medications (such as methimazole), radioactive iodine ablation, and surgery 1. The specific etiology determines the optimal therapeutic approach and prognosis.

Related Questions

What are the definitions and clinical features of mild, moderate, and severe hyperthyroidism?
What is the appropriate initial workup for a 32-year-old female with hyperthyroidism?
What is the recommended surveillance and treatment plan for a patient with hyperthyroidism, including those with Graves' disease and toxic multinodular goiter?
What are the typical symptoms of hyperthyroidism?
Does hyperthyroidism require hospitalization?
What is the recommended conservative management for a hemorrhagic ovarian cyst?
What is the optimal duration of levofloxacin 750 mg oral therapy for a 25-year-old male with uncomplicated urinary tract infection presenting with dysuria, no fever, and possible early prostatitis?
In a patient with an endometrioma and a CA‑125 level of 73 U/mL, should this result alter the current management plan?
In a patient using an Aircurve 10 adaptive servo‑ventilation (ASV) device with minimum EPAP 6 cmH₂O, maximum EPAP 15 cmH₂O, pressure support range 0–15 cmH₂O, average nightly use 4 h 26 min (43% of nights ≥4 h), median leak within normal limits, and an apnea‑hypopnea index (AHI) of 13.1, what adjustments to the EPAP, pressure support, and adherence strategy are recommended?
What is the appropriate management for a patient presenting with both hypermagnesemia and hypercalcemia?
Should I start lisinopril (an ACE inhibitor) in a normotensive patient with acute decompensated heart failure who is already on metoprolol and diltiazem, has good renal function, occasional systolic blood pressure in the 157 mm Hg range, bilateral pitting edema, no crackles, and no jugular venous distension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.